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4Abstract
Objectives: Active screening for celiac disease frequently detects seropositive children with
normal villous morphology (potential celiac disease). It remains unclear whether these
subjects should be treated. We here investigated the prevalence of anemia and iron deficiency
in children with potential and mucosal atrophy celiac disease.
Methods: The prospective study involved 19 children with potential disease, 67 with partial or
subtotal villous atrophy (P/SVA) and 16 with total villous atrophy (TVA). Twenty-three
healthy children comprised the control group. The groups were compared for various clinical,
histological and laboratory parameters and hepcidin.
Results: The prevalence of abnormal parameters was as follows (controls, potential celiac
disease, P/SVA and TVA, respectively): anemia 0%, 15%, 22% and 63%; low iron 5%, 0%,
14% and 50%; increased transferrin receptor 1 (TfR1) 5%, 16%, 20% and 47%; low ferritin
0%, 21%, 35% and 87%; and low transferrin saturation 10%, 11%, 41% and 71%. One
subject had low folate and none had low vitamin B12. The median values for hemoglobin,
total iron, ferritin and transferrin saturation were significantly lower and TfR1 values higher
in TVA group compared with other groups. After a median of seven months on a gluten-free
diet hemoglobin, total iron, ferritin and albumin in children with P/SVA exceeded the
baseline values in the potential celiac disease group.
Conclusions: The development of anemia and iron deficiency in celiac disease is a continuum
and may already be present in children with normal villous morphology, advocating an early
diagnosis and possible dietary treatment of these patients.
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5What is known
· An increasing number of children with positive celiac autoantibodies but
morphologically normal small-bowel mucosa are detected by active case-finding
and screening
· It remains unclear whether subjects with this so-called potential celiac disease
should be treated with a gluten-free diet
What is new
· Celiac disease-associated anemia and iron deficiency is a continuum and may
appear in seropositive children even before morphological villous damage
· These children may benefit of an early diagnosis and dietary treatment
6Introduction
Celiac disease is a life-long disorder characterized by a heterogeneous clinical picture.1
Recent screening studies have revealed the prevalence to be as high as 1-2% (2, 3). The only
treatment for the condition is a permanent gluten-free diet, which usually results in beneficial
clinical, histological and serological response (4). In all current criteria the diagnosis is still
based on the morphological damage of the small-bowel mucosa (6-8), although in the latest
pediatric guidelines the actual biopsy is not necessary in all cases (5). However, accurate
serological tests measuring antibodies against transglutaminase 2 (TG2-ab) and endomysium
(EmA) are nowadays available (5,9,10). Widespread utilization of these tests has resulted in
the identification of an increasing number of seropositive subjects who still have
morphologically normal mucosa and are thus not diagnosed (2, 11). Recent studies have
produced a growing body of evidence that this so-called potential celiac disease may in fact
already cause gluten-dependent symptoms before villous atrophy with crypt hyperplasia, the
end-stage of the disease, develops (11-13). Further, most of these cases will eventually
develop atrophy when continuing on a gluten-containing diet (12, 14-16). Interestingly,
clinical experience suggests that children with potential celiac disease evince signs of anemia
or subclinical iron deficiency. Besides a role in oxygen transport, iron plays a crucial part in
many biological functions such as energy production, DNA synthesis and cell proliferation,
and iron deficiency can impair psychomotor and cognitive development and lead to a
defective immune system (17-21). Thus, if abnormal iron parameters may be present already
in  children  with  potential  celiac  disease,  this  would  strongly  support  active  diagnosis  of
seropositive patients even before the development of advanced mucosal lesion.
The aim of the present prospective study was to investigate the prevalence of
anemia and abnormal iron parameters in children with potential and mucosal atrophy celiac
disease. Further, these variables and a variety of other clinical and laboratory features were
7compared between these seropositive patients with different stages of mucosal damage and
healthy controls.
Materials and methods
Patients and study design
The study was conducted at the Tampere Centre for Child Health Research, University of
Tampere and Tampere University Hospital. It involved consecutive children (age <16 years)
referred to our tertiary referral center due to celiac disease suspicion and evincing positive
celiac disease serology. Exclusion criteria were study refusal and negative or lacking
serology. All participants underwent a thorough clinical examination and blood sampling for
serology and laboratory parameters and for celiac disease genetics. Gastrointestinal
endoscopy with duodenal biopsies was performed under general anesthesia. Children with
established villous atrophy with crypt hyperplasia received a celiac disease diagnosis and
were placed on a gluten-free diet, while those with positive autoantibodies but
morphologically normal villi continued on a normal diet and comprised the potential celiac
disease group (for details see below). Children with potential celiac disease were monitored
every 3-6 months during the study period (up to 2.5 years) and a new endoscopy was
performed in case of marked increase in the antibody values or worsening of the symptoms.
Finally, all study parameters were compared between the study groups at the time of
diagnosis. After the patients with a celiac disease diagnosis had been on a gluten free diet for
a minimum of three months, the values of iron parameters were re-measured. Twenty-three
healthy children with no celiac disease suspicion and negative EmA and TG2-ab comprised
the non-celiac control group for comparisons of the study parameters. These children had
participated as family members in a celiac disease screening study in which blood samples
8were drawn for laboratory parameters and celiac disease serology and genetics as previously
described (10).
Written informed consent was obtained from all study participants and/or their
parents according to the Helsinki Declaration. The study protocol and patient recruitment
were approved by the Ethics Committee of the Pirkanmaa Hospital District.
Clinical Evaluation
The clinical presentation of celiac disease was recorded and categorized into gastrointestinal
symptoms (e.g. diarrhea, stomach pains, constipation, bloating), extra-intestinal symptoms
(e.g. neurologic symptoms, rash, poor growth, anemia, fatigue, arthralgia) or screen-detected
in at-risk groups (e.g. celiac disease in relatives or previous type 1 diabetes). In addition,
family history of celiac disease and presence of disease-associated (e.g. type 1 diabetes,
autoimmune thyroidal disease) or other chronic conditions were recorded. Height and body
mass index (BMI) at celiac disease diagnosis were expressed as standard deviation scores
(SDS) for age and sex.
Small-Bowel Mucosal Histology and IgA deposits
A minimum of five small-bowel mucosal biopsies were taken from the distal duodenum and
three biopsies from the anatomical duodenal bulb. The paraffin-embedded specimens were
cut, stained with hematoxylin and eosin and evaluated by experienced pathologists. Only
correctly oriented histological specimens with complete villus-crypt units and longitudinally
cut crypts were accepted for microscopic analyses (22). The specimens were further graded
on the basis of the histological findings as follows: morphologically normal villi with or
without mucosal inflammation (potential celiac disease group, equivalent to Marsh 0-1 or
Corazza-Villanacci A), normal villi with crypt hyperplasia (Marsh 2, Corazza-Villanacci A),
9subtotal and partial villous atrophy (P/SVA group, Marsh 3a-b, Corazza-Villanacci B1) and
total villous atrophy (TVA group, Marsh 3c, Corazza-Villanacci B2) (23, 24).
At least one biopsy from both the distal duodenum and the bulb area were freshly
embedded in optimal cutting temperature compound (OCT) (Tissue-Tec, Miles Inc, Elkhart,
IN, USA) and snap-frozen in liquid nitrogen. Staining of intraepithelial lymphocytes (IELs)
was performed with 5-µm-thick frozen biopsy sections. The mucosal CD3+ IELs were stained
with  monoclonal  antibody  Leu-4  (Becton  Dickinson,  San  Jose,  CA,  USA)  and  T-cell
receptor-γ antibody (Endogen, Woburn, MA, USA) was used to stain γδ+ IELs. A 100x flat
field light microscope objective was used to count positive IELs and counted cells were
expressed as cells/mm of epithelium (25). Celiac disease-specific mucosal TG2-targeted
autoantibody deposits (IgA deposits) were measured by direct immunofluorescence from the
frozen specimens as previously described (26, 27). In celiac disease the deposits are found
along the villous and crypt epithelium and around mucosal vessels, whereas in healthy
individuals IgA is detected only inside plasma and epithelial cells (27).
Celiac Disease Serology and HLA Genotype
Serum IgA class EmA titers were measured by indirect immunofluorescence (in-house) with
human umbilical cord as substrate. A dilution ≥ 1:5 was considered positive and positive sera
were further diluted 1:50, 1:100, 1:200, 1:500, 1:1000, 1:2000 and 1:4000. The EliA Celikey
test (Phadia, Uppsala, Sweden) was used to determine serum TG2-abs. Cut-off for TG2-ab
positivity was >7.0 U/l according to the manufacturer’s instructions.  Human leucocyte
antigen (HLA) DQ2/DQ8 genotyping was performed using the SSP low-resolution kit
(Olerup SSP AB, Saltsjöbaden, Sweden).
Laboratory Parameters and Hepcidin
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The following associated laboratory parameters were measured by standard methods:
hemoglobin (Hb, reference value (Rf) from 100-141 g/l to 130-160 g/l depending on age and
sex), plasma transferrin receptor 1 (TfR1, Rf from 1.6-5.2 mg/l to 2.0-6.8 mg/l), serum total
iron (Fe, Rf 6-25 µmol/l), plasma ferritin (Rf >10 µg/l), transferrin iron saturation (Rf 15-50
%), serum folate (Rf 10.4-42.4 nmol/l) and serum vitamin B12 (Rf 140-490 pmol/l). Serum
bioactive hepcidin (hepcidin-25) levels were measured with parallel samples using a
commercial solid-phase enzyme-linked immunosorbent assay (EIA-5258, DRG Diagnostics,
Marburg, Germany). Furthermore, values for plasma albumin (Rf from 35-46 g/l to 37-51 g/l
depending on age and sex), plasma alkaline phosphatase (ALP, Rf from 115-460 U/l to 80-
445 U/l), plasma alanine aminotransferase (ALT, Rf <40 U/l) and plasma thyroid-stimulating
hormone (TSH, Rf 0.27-4.2 mU/l) were measured by standard methods. Laboratory
parameters other than iron were measured in order to further elucidate the overall severity of
the disease in each group.
Statistics
Clinical characteristics and prevalence of abnormal blood parameters are presented as
percentage distributions. The skewedness of the quantitative data was assessed by the
Shapiro-Wilk method and most of the variables were not normally distributed. For simplicity,
all data are thus expressed as medians with quartiles or with range. Laboratory values
between groups were compared using the Kruskal-Wallis one-way analysis of variance or by
Fisher’s exact test. Changes within the groups on a gluten-free diet were compared using
either the paired t-test or Wilcoxon signed-rank test as appropriate. Chi-squared test or
Fisher’s exact test were used to compare the proportions of abnormal laboratory parameters
between the groups. P-values <0.05 were considered significant.
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Results
Altogether 102 children participated the study. Of them TVA was detected in 16, P/SVA in
67, and potential celiac disease in 19 subjects. None presented with crypt hyperplasia and
normal villi (Marsh 2). There were no differences in age or gender between the groups, except
a trend with a borderline significance (P=0.062) for lower number of girls in the control group
(Supplemental Table 1, supplemental digital content). Gastrointestinal presentation was more
common in the TVA than in the P/SVA or potential celiac disease, while the latter two groups
comprised more screen-detected children and those with extra-intestinal presentation.
Associated conditions and family history of celiac disease were more common in potential
celiac  disease.  By  definition,  all  102  patients  with  celiac  disease  suspicion  and  none  of  the
controls had positive TG2-ab and/or EmA. Also, HLA DQ2/8 was present in all seropositive
children and 59% of the controls (Supplemental Table 1, supplemental digital content).
Both EmA and TG2-ab differed significantly between the study groups, as their
concentrations increased parallel with the severity of mucosal damage (Table 1). Similarly,
the densities of CD3+ and γδ+ IELs increased gradually from potential celiac disease to TVA.
There were no differences between the groups in any of the non-iron related laboratory
parameters or in height and BMI-SDS, but in ALT there was an increase towards significantly
higher values in TVA. TG2-targeted mucosal IgA deposits were positive in all seropositive
children except two with P/SVA and one with potential celiac disease; in the three negative
cases there was possible patchy distribution of the deposits (Table 1).
Anemia, low iron, high TfR1, low ferritin and decreased transferrin saturation
were more common in children with advanced histological damage (Table 2). Nevertheless,
anemia and abnormal TfR1, ferritin and transferrin saturation were also present in a number
of subjects with potential celiac disease (Table 2). Furthermore, all these laboratory
abnormalities except low iron were more common in potential celiac disease group than in
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controls. Of the three potential celiac disease patients presenting with anemia one had Marsh
0  (CD3+  IELs  25  cell/mm)  and  the  others  Marsh  1  lesion,  but  all  had  increased  γδ+  IELs
(10.5 cells/mm, 25.1 cells/mm and 12.6 cells/mm) and positive EmA (1:200, 1:50 and 1:100)
and  IgA  deposits.  Their  ferritin  values  were  28  µg/l,  6  µg/l  and  6  µg/l.  Besides  these  three
with  anemia,  two  potential  celiac  disease  patients  (Marsh  0,  EmA  1:50  and  Marsh  1,  EmA
1:200) had high TfR1 (6.5 mg/l and 5.1 mg/l) and low/borderline low ferritin (7 µg/l and 10
µg/l) and transferrin iron saturation (14.2% and 17.3%).  These children were between 3.5-7.2
years of age, except one girl age of 15 years of whom there was no information of excessive
or prolonged menstruation, and no other pathological or dietary causes of anemia except
potential celiac disease were detected. A low folate value was seen only in one patient with
SVA and low vitamin B12 in none of the study children (Table 2).
The median values for hemoglobin, total iron, ferritin and transferrin iron
saturation were significantly lower and TfR1 higher in TVA group compared with the other
groups (Figure 1). In contrast, there were no differences in any of these parameters between
the potential celiac disease and P/SVA groups, and both had significantly lower ferritin than
the control group. There were no differences between the study groups in the median hepcidin
levels (Figure 1). Furthermore, there were no differences in hepcidin concentrations between
subgroups  with  or  without  anemia,  or  with  or  without  low  ferritin  (data  not  shown).  In  the
clinical presentation between the potential celiac disease children with or without anemia
there were no significant differences as 78% of those presenting with anemia/iron deficiency
suffered from gastrointestinal or extraintestinal symptoms while the corresponding figure was
90% in those with normal hemoglobin and iron parameters. There were also no correlations
between hepcidin and hemoglobin or ferritin values (data not shown).
After  an  average  of  seven  (range  3-13)  months  on  a  gluten-free  diet  the
hemoglobin, TfR1, total iron, ferritin and albumin values improved significantly within both
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the TVA and the P/SVA groups (Figure 2). When these follow-up values were compared with
the baseline values in the potential celiac disease group, albumin in TVA group (p=0.037)
was  found  to  be  significantly  higher.  A  similar  but  non-significant  trend  was  also  seen  in
P/SVA group in total iron, ferritin and albumin (Figure 2). Anemia was still present in one
(2.5%)  of  the  P/SVA  patients  and  none  of  the  TVA  patients  in  whom  it  was  re-evaluated
while on the dietary treatment.
Three children with potential celiac disease started a gluten-free diet while still
having  normal  villi.  One  of  them  was  anemic  at  baseline  and  while  on  diet  had  increased
hemoglobin and total iron values. Another child experienced similar improvements even
though he was not anemic at baseline. In the third case there were no marked changes in the
laboratory values. All but two of the remaining 16 children have remained seropositive during
a follow-up of up to 2.5 years. Furthermore, two potential celiac disease children with anemia
started an iron substitution without gluten-free diet and also experienced improved
hemoglobin and iron parameters.
Discussion
The main finding in the present prospective study was that, even if more common in children
with severe mucosal atrophy, celiac disease-associated anemia and iron deficiency is a
continuum and may appear even before morphological villous damage. Further, there were no
significant differences in the iron parameters between the seropositive subjects with
diagnostic PVA or SVA (Marsh 3a-b) and those with the currently non-diagnostic potential
celiac disease (Marsh 0-1).
Anemia and iron deficiency are among the most common abnormal findings in
untreated celiac disease (28). Accordingly, anemia was seen here in approximately one fifth
of children with P/SVA and two thirds of those with TVA. Notwithstanding this correlation
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with the severity of the histology, it is noteworthy that anemia was also present in 15% of the
otherwise healthy potential celiac disease patients with no other obvious reason for the low
hemoglobin.  Moreover,  while  still  evincing  normal  villi  these  seropositive  children  also  had
abnormalities in many other iron parameters more often than controls, of whom almost none
presented with even subclinical anemia. This issue has not hitherto been investigated
systematically, but a few earlier studies have in fact pointed in the same direction. In a
prospective Italian study by Tosco and colleagues none of the 106 children with potential
celiac disease had anemia at baseline, but four presented with low ferritin, and during a
follow-up of up to three years on a gluten-containing diet four developed anemia (14). In our
previous adult study three out of 11 seropositive subjects with mild enteropathy (Marsh 1-2)
presented with malabsorption or anemia (29), this again being in line with the present
findings.
Compatible with the proportion of abnormal iron parameters, also the absolute
values were inferior in the TVA group compared with the other three groups. Notably,
however, there were no significant differences between potential celiac disease and P/SVA,
while in contrast both groups had lower median ferritin than the control children. In addition,
on  a  gluten-free  diet  several  of  the  iron  parameters  within  the  P/SVA  and  TVA  groups
improved to levels even better than those in the potential celiac disease patients on a normal
gluten-containing diet, suggesting that the latter group already had sub-optimal values. In line
with this we have previously observed improved hemoglobin values in EmA-positive children
and adults who had mild enteropathy (Marsh 1-2) and were placed on an experimental gluten-
free diet for one year (11, 12). These results demonstrate that, despite the differences in
histology and serology, the distinction between potential celiac disease and in particular
P/SVA is at least partly artificial and based more on simplified histological classification than
on the actual biological nature of the disease.
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Somewhat surprisingly we found neither differences in hepcidin values between
the groups nor correlations between hepcidin and other iron parameters. Hepcidin is the key
player in iron metabolism, as it regulates both intestinal absorption and release of iron from
the body storages (18). Hitherto only a few studies have investigated hepcidin in the context
of celiac disease. Bergamaschi and co-authors also found no correlation between hepcidin and
anemia or other iron parameters in adults (30). However, they measured the less accurate pro-
hepcidin instead of the actual functional hepcidin-25 used here (30, 31). In a sole pediatric
study (only abstract available) the majority of children with villous atrophy celiac disease had
low hepcidin, but in 20% it was increased and the authors speculated that they had anemia of
chronic disease (32). This type of anemia is associated with high levels of pro-inflammatory
cytokines, as seen for example in inflammatory bowel disease, in which a correlation between
anemia and high hepcidin values has been observed (21, 33). Interestingly, although no
differences between the groups were found in our study, there was a wide variation in
hepcidin values, indicating that anemia in individual patients is caused by variable factors, as
previously shown (34). Furthermore, the fact that two children here presented with anemia or
low ferritin despite apparently completely normal duodenal mucosa (Marsh 0) suggests that
iron metabolism might be disturbed even before marked intestinal inflammation. Indeed,
Borrelli and colleagues (35) recently demonstrated activation of different immunoregulatory
reactions even in such early potential celiac disease which could possibly affect iron
metabolism (36). This could also explain the changes observed in sensitive iron parameters,
especially the significantly lower ferritin values in potential celiac disease group compared
with the controls (37). Further studies of the mechanisms of anemia in early developing celiac
disease are evidently needed.
Currently the diagnosis of potential celiac disease remains unclear. For example,
in the new ESPGHAN guidelines measurement of γδ+ IELs and IgA deposits in patients with
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Marsh 1 is suggested, but there is no conclusion as to their diagnosis (5). As a result of active
screening for celiac disease the number of these seropositive individuals is constantly rising
and, in consequence, also their natural history has been increasingly investigated (12, 14, 38-
40). In two recent Italian studies symptomatic children with potential celiac disease were
placed on a gluten-free diet, while the rest continued on a normal diet (14, 38). All patients on
diet became seronegative and most had a positive clinical response, while after nine years
67% of those on gluten still had normal villi (14, 38). None of the 16 children continuing on a
gluten containing diet in the present study have yet developed mucosal atrophy, although
control endoscopy was not done systemically to all. This is in contrast with our previous study
where this was in most cases already seen after one year (12). However, the children in the
earlier study had more advanced clinical and histological disease at baseline. It is also
noteworthy that two of the potential celiac disease patients here seroconverted to negative.
Such a fluctuation in low antibody levels has been shown before, especially in asymptomatic
cases (39, 41). In these circumstances additional evidence of celiac disease, such as the
appropriate genetics, positive EmA, IgA deposits and refined antibody tests are of particular
importance (40-42). In sum, it is evident that the presentation and natural history of potential
celiac disease is variable, but it would appear that a part of these subjects may present with
clinical symptoms and signs and benefit from early dietary therapy. Considering the essential
role of iron in human health, our further support at least a possibility of an early diagnosis and
treatment of these children.
The major strengths of the present study are the prospective design and the variety
of clinical, histological and serological parameters measured. Furthermore, particular
attention was paid to the precise histomorphological analysis of the biopsies and thus correct
histological grouping of the participants. The main limitation is the relatively small number of
children with potential celiac disease which hampers statistical evaluation. In addition, since
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currently it is not recommend to set an official diagnosis in children with potential celiac
disease in Finland, it was not possible to systematically evaluate the effect of a gluten-free
diet  on  their  hemoglobin  and  iron  parameters.  Since  the  main  aim  of  the  study  was  not  to
investigate the natural history of potential celiac disease patients the overall duration of the
study was rather short, and obviously careful long-term follow-up of these cases is necessary.
It  must  also  be  mentioned  that  the  follow-up values  of  iron  parameters  in  P/SVA and TVA
patients were not systemically collected from all patients who had normal values at the time
of celiac disease diagnosis. Finally, the number of control children was rather small, even
though we believe that they were a representative of the Finnish population in respect of iron
parameter levels (43). Further, as these children belong to families where celiac disease is
present they also have an increased risk for the condition and, on the other hand, possibly
reduced daily gluten consumption.
In conclusion, we showed that the development of anemia and subclinical iron
deficiency in celiac disease is a continuum and may already appear in seropositive children
with morphologically normal mucosa. These findings support early diagnosis and either
careful follow-up or alternatively active dietary treatment of children with potential celiac
disease.
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Figure legends
Figure 1. Hemoglobin (A), transferrin receptor 1 (B), total iron (C), ferritin (D), transferrin
iron saturation (E) and hepcidin (F) values in 23 healthy children, in 19 children with
potential celiac disease (potential CD), in 67 children with partial or subtotal villus atrophy
(P/SVA)  and  in  16  children  with  total  villus  atrophy  (TVA).  The  values  are  presented  as
medians with quartiles (boxes) and range (whiskers). Only significant differences between the
groups are shown (brackets).
Figure 2. Hemoglobin (A), transferrin receptor 1 (B), total iron (C), ferritin (D) and albumin
(E)  in  19  children  with  potential  celiac  disease  (potential  CD),  67  children  with  partial  or
subtotal (P/SVA) and 16 children with total villus atrophy (TVA) at the time of endoscopy and
after an average of seven months on a gluten-free diet (only P/SVA and TVA). The values are
shown as medians and quartiles. Only significant changes within the groups are shown
(brackets).
Supplemental Table 1. Supplemental digital content. Baseline characteristics in 19 children
with potential celiac disease, 83 with villous atrophy celiac disease and in 23 non-celiac
controls.
Captions in the text:
“There were no significant differences in age or gender between the groups (Supplemental
Table 1, supplemental digital content).”
“By definition, all 102 patients with celiac disease suspicion and none of the controls had
positive TG2-ab and/or EmA. Also, HLA DQ2/8 was present in all seropositive children and
59% of the controls (Supplemental Table 1, supplemental digital content).”
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Table 1. Baseline characteristics in 19 children with potential celiac disease, 83 with villous atrophy celiac disease and in
23 non-celiac controls.
Potential celiac
disease, n=19
Celiac disease n=83 Non-celiac
controls, n=23P/SVA, n=67 TVA, n=16
% % % %
Age, median (range), years 6.3 (3.5-16.9) 7.5 (1.6-15.2) 6.1 (3.7-15.6) 6.0 (2.1-11.4)
Girls 74 73 69 44
Clinical presentation
Gastrointestinal1 72 75 94 ND
Extra-intestinal2 17 22 6 ND
Screen-detected3 11 3 0 ND
Celiac disease in family 72 47 33 ND
Associated disease4 10 1 6 ND
Other chronic disease5 26 37 50 ND
Positive EmA/TG2ab 100 100 100 0
HLA DQ2/8 100 100 100 59
1Diarrhea, stomach  pains, constipation, bloating
2Rash, dizziness, retarded growth, anemia, iron deficiency, leg pains, tiredness, arthralgia
3Family risk of celiac disease, previous type 1 diabetes
4Type 1 diabetes, autoimmune thyroidal disease
5 Rheumatoid arthritis, allergies, congenital glaucoma, asthma, atopic dermatitis, anorexia nervosa
ND, no data; HLA DQ2/8, celiac disease-associated human leucocyte antigen
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Table 2. Baseline laboratory parameters, anthropometric data and small-bowel mucosal histology in 19 children with
potential celiac disease and 83 with villous atrophy celiac disease. Values except transglutaminase 2 targeted IgA
deposits are shown as medians with lower and upper quartiles.
Potential
celiac disease
n=19
Celiac disease n=83
P valueP/SVA
n=67
TVA
n=16
EmA, titer 1:50 (1:5, 1:100) 1:500 (1:100, 1:2000) 1:1500 (1:500, 1:4000) <0.001
TG2 antibodies, U/l 24.5 (10.3, 33.0) 70.0 (21.0, 120.0) 120.0 (120.0, 120.0) <0.001
Albumin, g/l 38.0 (36.5, 39.5) 38.0 (35.0, 40.0) 37.0 (36.0, 39.0) 0.517
ALP, U/l 225 (182, 265) 206 (135, 222) 214 (128, 237) 0.429
ALT, U/l 14.0 (12.0, 17.5) 17.0 (14.0, 24.3) 21.5 (16.5, 34.5) 0.032
TSH, mU/l 3.2 (2.7, 3.9) 2.1 (1.6, 3.2) 3.7 (2.95, 7.2) 0.323
Height, SD -0.4 (-1.6, 0.3) 0.0 (-1.1, 0.8) -0.4 (-0.7, 0.9) 0.178
BMI, kg/m2 16.0 (15.3, 21.2) 11.2 (14.6, 17.7) 17.3 (15.9, 18.5) 0.768
CD3+ IELs, cells/mm 46 (24, 61) 92 (75, 111) 105 (95, 151) <0.001
γδ+ IELs, cells/mm 22.0 (9.4, 35.1) 39.5 (25.9, 54.6) 34.4 (21.9, 52.5) 0.002
Positive IgA deposits, % 94 97 100 0.576
EmA, endomysial antibodies; TG2, transglutaminase 2; ALP alkaline phosphatase; ALT, alanine aminotransferase; TSH,
thyroid-stimulating hormone; BMI, body mass index; IEL, intraepithelial lymphocyte
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Table 3. Percentages of anemia and abnormal iron parameters in 23 non-celiac controls, 19 children with potential celiac
disease and 83 with villous atrophy celiac disease.
Non-celiac
controls
n=23
Potential
celiac disease
n=19
Celiac disease n=57
P valueP/SVAn=67
TVA
n=16
% % % %
Anemia 0.0 15.3 22.4 62.5 <0.001
Low total iron 4.8 0.0 13.6 50.0 <0.001
High TfR1 4.8 15.8 20.4 46.7 0.002
Low ferritin 0.0 21.1 35.2 86.7 <0.001
Low transferrin saturation 9.5 11.1 40.5 71.4 <0.001
Low vitamin B12 0.0 0.0 0.0 0.0 1.000
Low erythrocyte folate 0.0 0.0 2.3 0.0 1.000
TfR1, transferrin receptor 1
Low denotes values below reference values. High denotes values above reference values.
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